DYSPAREUNIA: CMS CLARIFICATION RESULTS IN EXPANDED TREATMENT AND COVERAGE UNDER MEDICARE PART D
- Published: Thursday, 10 May 2018
ISSWSH is pleased to announce and recognize the Centers for Medicare and Medicaid Services (CMS) clarification of the statutory intent of “Prescription Drug Benefits” section 1860D-2(e)(2)(A) of the Social Security Act, stating that drugs for the treatment of moderate to severe dyspareunia (pain during sexual intercourse) due to menopause, are not excluded from Medicare Part D coverage when used consistent with this labeling.
ISSWSH, alongside the North American Menopause Society (NAMS), the American College of Obstetricians and Gynecologists (ACOG), and many other interested parties are committed to women’s health and particularly sexual health. James A. Simon, MD, President of ISSWSH, thanks these partners and commends CMS for this clarification that now allows women suffering from dyspareunia, to access expanded treatment options and get coverage under Medicare Part D.
View Press Release